Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.56 |
| ▸ | SCN4A | P35499 | 4/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexpramipexole SCHEMBL74780 | 1.00 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL195775 | 1.00 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL2995942 | 0.99 | ADRA2A (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL1193565 | 0.99 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL4144177 | 0.99 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL4099920 | 0.99 | ADRA2A (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL3947668 | 0.99 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL42113 | 0.99 | ADRA2A (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL20524815 | 0.99 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Dexpramipexole SCHEMBL910147 | 0.99 | ADRA2A (1.00) | DRD3DRD2HRH2ADRA2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28120 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026106939-A1 | IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-121550470-B | High-adhesion porous sponge and preparation method and application thereof | 国科温州研究院(温州生物材料与工程研究所) | 2026-05-19 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260131140-A1 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIV (US) | 2026-05-14 | — | — | US | claimed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | claimed |
| WO-2000054773-A1 | DOPAMINE AGONISTS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-0989850-A1 | USE OF PRAMIPEXOLE IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2000-04-05 | — | — | EP | claimed |
| CN-1243439-A | Use of prumipexole in the treating of restless legs syndrome | UPJOHN CO (US) | 2000-02-02 | — | — | CN | claimed |
| US-6001861-A | Use of pramipexole in the treatment of restless legs syndrome | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-14 | — | — | US | claimed |
| WO-1999059563-A2 | CABERGOLINE AND PRAMIPEXOLE FOR TREATING CNS DISEASES, ESPECIALLY PARKINSON'S DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| WO-1999036095-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 1999-07-22 | — | — | WO | claimed |
| WO-1998031362-A1 | USE OF PRAMIPEXOLE IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 1998-07-23 | — | — | WO | claimed |
| US-5650420-A | Pramipexole as a neuroprotective agent | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-22 | — | — | US | claimed |
| EP-0417637-A2 | Use of dopamine autoreceptor agonists in the treatment of drug dependency | BOEHRINGER INGELHEIM KG (DE) | 1991-03-20 | — | — | EP | claimed |